Strides Pharma Science Ltd

Strides Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Strides Pharma Science Ltd

₹ 837 -4.30%
01 Aug - close price
strides.com BSE: 532531 NSE: STAR
About

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]

Key Points

Business Segments
1) Pharma Generics: Its generic pharma business is driven by IP-based product licensing and global marketing and distribution partnerships. It specializes in manufacturing niche generic formulations in various dosage forms, like tablets, capsules, liquids, and sachets, focusing on regulated markets including the United States, Europe, Australia, etc. It has emerged as one of the world’s leading producers of soft gelatin capsules. [1] [2]

Website BSE NSE
  • Market Cap ₹ 7,711 Cr.
  • Current Price ₹ 837
  • High / Low ₹ 972 / 465
  • Stock P/E 125
  • Book Value ₹ 346
  • Dividend Yield 0.48 %
  • ROCE 4.66 %
  • ROE 85.9 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company has delivered good profit growth of 89.9% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 28.8%
  • Company has been maintaining a healthy dividend payout of 114%

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 4.81% over past five years.
  • Promoter holding is low: 28.3%
  • Promoters have pledged or encumbered 50.1% of their holding.
  • Company has high debtors of 248 days.
  • Working capital days have increased from 57.4 days to 82.8 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
423 481 387 564 475 553 380 603 586 520 551 556 499
484 487 341 444 420 514 378 492 520 464 477 488 431
Operating Profit -61 -6 46 119 56 38 1 111 66 55 74 68 67
OPM % -14% -1% 12% 21% 12% 7% 0% 18% 11% 11% 13% 12% 13%
7 20 30 11 12 19 60 -1 8 24 2 12 2
Interest 26 35 35 43 37 42 36 39 48 42 34 29 30
Depreciation 24 24 22 23 21 23 22 22 22 21 21 22 22
Profit before tax -104 -44 18 65 9 -7 3 49 4 16 21 28 16
Tax % -36% -91% 30% 4% 12% -1% 112% -6% 33% -5% 30% 43% 19%
-66 -4 13 62 8 -7 -0 52 2 17 15 16 13
EPS in Rs -7.38 -0.44 1.39 6.91 0.89 -0.75 -0.04 5.65 0.26 1.88 1.62 1.75 1.45
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 15m Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
1,064 929 2,162 1,382 1,470 1,537 1,692 1,858 1,979 1,854 1,866 2,139 2,125
914 795 1,894 1,255 1,271 1,402 1,487 1,698 1,902 1,755 1,715 1,877 1,860
Operating Profit 150 134 268 127 199 135 205 159 77 100 151 263 265
OPM % 14% 14% 12% 9% 14% 9% 12% 9% 4% 5% 8% 12% 12%
4,614 619 82 154 860 111 93 117 123 68 122 2,873 40
Interest 105 34 103 72 82 54 67 65 74 139 139 146 136
Depreciation 47 49 103 70 78 83 94 99 104 94 87 85 86
Profit before tax 4,612 669 145 139 899 109 136 112 22 -65 46 2,905 82
Tax % 24% 20% 10% 22% 1% -1% 12% 30% -738% -107% 3% 1%
3,513 532 130 109 892 110 120 78 180 5 45 2,886 62
EPS in Rs 589.42 89.32 14.58 12.14 99.62 12.33 13.42 8.72 20.07 0.52 4.85 313.04 6.70
Dividend Payout % 86% 121% 34% 37% 2% 24% 104% 29% 0% 289% 52% 1%
Compounded Sales Growth
10 Years: 9%
5 Years: 5%
3 Years: 3%
TTM: 0%
Compounded Profit Growth
10 Years: 37%
5 Years: 90%
3 Years: 154%
TTM: 210%
Stock Price CAGR
10 Years: 3%
5 Years: 31%
3 Years: 72%
1 Year: 65%
Return on Equity
10 Years: 14%
5 Years: 19%
3 Years: 29%
Last Year: 86%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 60 60 89 89 90 90 90 90 90 90 92 92
Reserves 1,571 1,415 3,068 3,143 3,073 3,167 3,069 3,158 3,317 3,365 3,436 3,101
473 405 1,545 1,608 606 811 902 917 1,284 1,414 1,688 1,202
337 273 602 641 517 595 616 1,056 743 750 687 636
Total Liabilities 2,440 2,152 5,304 5,481 4,285 4,663 4,677 5,221 5,434 5,620 5,902 5,031
381 394 984 1,194 564 574 651 644 617 597 747 767
CWIP 37 39 180 158 144 122 112 111 56 55 107 106
Investments 1,047 968 2,447 2,520 1,777 2,149 2,171 2,395 2,400 2,492 2,364 1,848
976 750 1,693 1,609 1,801 1,818 1,743 2,072 2,361 2,476 2,684 2,311
Total Assets 2,440 2,152 5,304 5,481 4,285 4,663 4,677 5,221 5,434 5,620 5,902 5,031

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-3 207 83 412 66 40 138 283 -283 242 -14 421
3,999 305 -1,062 -883 433 -166 63 -276 19 -183 -69 -138
-3,498 -802 1,571 -67 -707 123 -204 -49 251 11 93 -370
Net Cash Flow 497 -290 592 -538 -208 -3 -3 -42 -13 70 11 -86

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 94 101 117 143 112 138 141 161 239 257 306 248
Inventory Days 80 110 113 204 126 197 189 254 170 168 188 145
Days Payable 127 133 148 234 183 212 200 271 213 220 205 163
Cash Conversion Cycle 47 77 82 112 55 123 130 144 196 205 289 230
Working Capital Days 34 33 28 -61 1 -14 -37 16 22 48 41 83
ROCE % 11% 9% 6% 5% 24% 4% 5% 4% 2% 2% 2% 5%

Shareholding Pattern

Numbers in percentages

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
31.08% 30.90% 28.28% 28.08% 27.79% 27.39% 25.88% 25.86% 25.84% 26.82% 28.30% 28.30%
21.43% 18.98% 18.85% 16.72% 17.25% 19.45% 24.57% 26.71% 30.08% 28.48% 28.32% 28.02%
15.07% 18.44% 17.88% 19.60% 19.50% 19.02% 17.66% 18.17% 18.24% 16.92% 13.72% 13.30%
0.40% 0.40% 0.40% 0.40% 0.40% 0.39% 0.39% 0.39% 0.01% 0.01% 0.01% 0.01%
32.05% 31.29% 34.60% 35.22% 35.06% 33.75% 31.52% 28.87% 25.83% 27.78% 29.65% 30.38%
No. of Shareholders 1,30,6821,23,9641,20,9161,12,7751,01,63891,18284,69591,91796,0091,14,23695,12592,889

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls